barbell

Big arm day... That decline barbell bench press is really paying off

matched text: “barbell”

The post-2002 collapse in hormone therapy prescribing was a real overcorrection, and the menopause content space deserves credit for dragging the topic back into the exam room. But it has overreached in three big places. Here's where the influencer messaging breaks from the evidence, and how to tell the difference. Dr. Jordan Feigenbaum and Dr. Austin Baraki separate what's right from what's oversold: the undertreatment problem, the "perimenopause is universal chaos" framing, the habit of blaming every midlife symptom on estrogen, and hormone therapy positioned as a default for everyone. They dig into the "musculoskeletal syndrome of menopause," testosterone for women (and its single guideline-supported use), compounded "bioidentical" hormones versus FDA-approved options, and why DUTCH urine panels don't guide care. Closes with the three big takeaways from the series. This is the final segment of Episode 1 in Barbell Medicine's menopause series. ⚠️ This content is for general education and is not medical advice. Talk to your own clinician about your individual symptoms, history, and treatment. Timestamps: 00:00 What the menopause content space gets RIGHT 00:23 Undertreatment and the menopause training gap 00:53 Overreach #1: perimenopause as universal chaos 01:31 Overreach #2: blaming every symptom on hormones 02:24 Overreach #3: hormone therapy as a default for everyone 03:15 The balanced view: appreciation plus reframing 04:58 "Musculoskeletal syndrome of menopause": is it real? 06:05 Testosterone for women: one evidence-based use 07:16 Why supraphysiologic dosing is a problem 08:37 Compounded "bioidentical" hormones vs FDA-approved 10:34 What FDA approval actually buys you 12:31 DUTCH panels and salivary hormone tests 14:46 The patient on pellets at 2x normal testosterone 16:57 Closing thoughts: who to follow in this space 17:37 Takeaway 1: 200 years of medicalizing menopause 18:05 Takeaway 2: what 24 years of WHI follow-up revised 18:55 Takeaway 3: match the intervention to the indication 19:44 Next episode + wrap RESOURCES: Subscribe to BBM Plus for the full unabridged Direct Line: https://barbellmedicine.supercast.com/ Barbell Medicine coaching and templates: https://www.barbellmedicine.com/ Signal book pre-order: https://www.barbellmedicine.com/shop/learning/signal/ Impact of Menopause Symptoms on Women in the Workplace (Faubion et al., Mayo Clinic Proceedings 2023): https://pubmed.ncbi.nlm.nih.gov/37115119/ Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis et al., 2019): https://pubmed.ncbi.nlm.nih.gov/31474158/ The Clinical Utility of Compounded Bioidentical Hormone Therapy (National Academies of Sciences, Engineering, and Medicine, 2020): https://www.nationalacademies.org/read/25791/chapter/1 SWAN (Study of Women's Health Across the Nation) — cohort behind the joint-pain and symptom-attribution figures: https://pubmed.ncbi.nlm.nih.gov/23788671/ WHI 18-year mortality follow-up (Manson et al., JAMA 2017): https://pubmed.ncbi.nlm.nih.gov/28898378/ WHI 20-year breast cancer follow-up (Chlebowski et al., JAMA 2020): https://pmc.ncbi.nlm.nih.gov/articles/PMC7388026/ — #menopause #perimenopause #hormonetherapy #HRT #testosterone #bioidenticalhormones #DUTCHtest #womenshealth #barbellmedicine #evidencebasedmedicine

matched text: “barbell”